Lupin receives USFDA’s approval for Tadalafil Tablets

27 Mar 2019 Evaluate

Lupin has received approval for its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and Company’s Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.

Lupin’s Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, is the generic equivalent of Eli Lilly and company’s Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg (RLD: Cialis) had annual sales of approximately $1780 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2114.10 33.75 (1.62%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×